Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS)

References

• Stephen F. Polycystic ovary syndrome. N Engl J Med 1995;333:1435
   Web of Science ®Google Scholar
• Wood JR, Ho CK, Nelson-Degrave VL, et al. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 2004;63:51–60
   PubMed Web of Science ®Google Scholar
• Sophie J, Didier D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107–17
   PubMed Web of Science ®Google Scholar
• John EN. Metformin for the treatment of the polycystic ovary syndrome. New Engl J Med 2008;358:47–54
   PubMed Web of Science ®Google Scholar
• Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35–43
   PubMed Web of Science ®Google Scholar
• Krentz AJ, von Muühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose–effect association with prevalent cardiovascular disease. Menopause 2007;14:284–92
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661–5
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–35
   PubMed Web of Science ®Google Scholar
• Talbott EO, Guzick DS, Sutton-Tyrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–21
   PubMed Web of Science ®Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562–8
   PubMed Web of Science ®Google Scholar
• (a) Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001;7:3–7. (b) Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000;26:151–7
   Google Scholar
• Ricardo A, Enrico C, Didier D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metabol 2006;91:4237–45
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: current and future treatment options. Paediatr Drugs 2006;8:311–18
   PubMedGoogle Scholar
• Alejandro G, Eduardo A, Alfredo R, et al. CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metabol 2002;87:3971–6
   PubMed Web of Science ®Google Scholar
• Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163–75
   PubMed Web of Science ®Google Scholar
• Zawadski JK, Dunaif A, Givens JR, et al., eds. Diagnostic criteria for polycystic ovary syndrome: in polycystic ovary syndrome. Boston (MA): Blackwell Scientific; 1992:377–84
   Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on the diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248–56
   PubMed Web of Science ®Google Scholar
• Jonard S, Robert Y, Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 2005;20:2893–8
   PubMed Web of Science ®Google Scholar
• Stacey G, Liuda Z, Diana T. SNP genotyping using the sequenom MassARRAY iPLEX Platform. Curr Prot Hum Genet 2.12.1-2.12.18, January 2009
   Google Scholar
• Vollmert C, Hahn S, Lamina C, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. Am J Physiol Endocrinol Metabol 2007;292:E836–44
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Schwarz PE, Hara M, et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1669–73
   PubMed Web of Science ®Google Scholar
• Wiltgen D, Furtado L, Kohek MB, Spritzer PM. CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome. Gynecol Endocrinol 2007;23:173–8
   PubMed Web of Science ®Google Scholar
• Michael W. O'Reilly, Angela ET, Nicola JC, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014;99:1027–36
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Yurtçu E, Demirci H, et al. Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. J Endocrinol Invest 2009;32:13–17
   PubMed Web of Science ®Google Scholar
• Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: an endocrinological perspective from the European Society of Endocrinology. EJE-14-0253
   Google Scholar
• Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metabol 2007;18:280–5
   PubMed Web of Science ®Google Scholar
• Pirwany IR, Fleming R, Greer IA, et al. Lipids 1681 and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxford) 2001;54:447–53
   PubMed Web of Science ®Google Scholar
• Macut D, Damjanović S, Panidis D, et al. Oxidised low-density lipoprotein concentrations: early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 2006;155:131–6
   PubMed Web of Science ®Google Scholar
• Xu XF, De Pergola G, Bjorntorp P. Testosterone increases lipolisi and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991;128:379–82
   PubMed Web of Science ®Google Scholar
• Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 1762 2001;103:1410–15
   PubMed Web of Science ®Google Scholar
• Diao XH, Shi YH, Gao Q, et al. Relationship between single nucleotide polymorphism-56 of calpain-10 gene and glucose and lipid metabolism in polycystic ovary syndrome patients. Zhonghua Fu Chan Ke Za Zhi 2008;43:106–9
   PubMedGoogle Scholar